SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Hot inflation data revived fears of further Fed rate hikes, while weakness in AI and semiconductor stocks intensified the broad market selloff. Traders debated whether the pullback is a buying opportunity or the start of a deeper correction, with producer-price data seen as a key next test.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A hotter-than-expected inflation reading revived fears of further Fed rate hikes, while weakness in semiconductors and AI-linked stocks intensified pressure on QQQ. Traders debated whether the selloff signals a deeper unwind of the AI trade or a buying opportunity, with upcoming inflation data and TSMC results seen as potential tests of market direction.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Gartners warning that most independent neocloud providers may not survive has intensified concerns about CoreWeaves debt-heavy expansion, while bond-market stress and inflation-driven rate fears have added pressure. Traders are split between fears of refinancing trouble and an AI infrastructure downturn, and dip-buying arguments that its contract backlog and industry demand can support the business.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is sliding with AI-infrastructure peers amid concern over Gartners warning that many independent neocloud providers may not survive independently, compounded by hot inflation data and worries about financing costs after CoreWeaves debt came under scrutiny. Traders are split between buying the pullback on belief that AI demand remains strong and fearing that high capital needs and borrowing costs could undermine the sectors business model.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Hotter-than-expected inflation and fears of further Fed tightening are weighing on Nvidia amid a broad tech and semiconductor selloff. Traders also debate whether AI spending and financing risks point to a deeper bubble unwind, while others see the pullback as a buying opportunity and remain confident in demand.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

The FDA expanded Anktivas approval to include BCG-unresponsive papillary-only bladder cancer, broadening its eligible patient population. Traders largely view the decision as a significant commercial and regulatory positive, but many are frustrated by the muted share-price response, debating whether the news was priced in or held back by short selling, while some cite valuation and dilution risks.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs Neutron debut was pushed into 2027 after manufacturing defects were found in a first-stage carbon-composite dome, prompting a sharp selloff. Traders are divided between frustration over repeated delays and concerns about execution, costs, and competition, and the view that fixing the issue before flight is the prudent choice; broader weakness in growth and space stocks is also weighing on sentiment.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is under pressure amid a broader Korean-market and memory-stock selloff, with traders focused on fears that Chinese memory maker CXMT could become a stronger competitor and on concerns about AI spending and demand. Some traders view the competition threat as premature and the drop as overdone, arguing that SK Hynixs HBM position and AI-driven memory demand remain supportive.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor selloff, with traders citing inflation and rate concerns alongside worries about AI valuations and Chinese chip competition. Dip buyers argue demand and chip-company fundamentals remain strong, while bears expect further declines; the ETFs 3x leverage intensifies the swings.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins prolonged slide to fresh 52-week lows, alongside repeated analyst price-target cuts and broader tech-market weakness, dominates discussion. Holders are split between viewing the companys growth and cash generation as undervalued and fearing more downside, with many waiting for earnings and guidance to clarify the outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist 

Equity

JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.

These Analysts Slash Their Forecasts On Abivax Following H1 Results

Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.read more...

Earnings Scheduled For September 21, 2026

Companies Reporting Before The Bell
 Ennis (NYSE:EBF) is expected to report earnings for its second quarter.
Companies Reporting After The Bell
 Abivax (NASDAQ:ABVX) is projected to report quarterly loss at $1.08 perread more...

Accenture, Abivax and 3 Stocks to Watch Heading Into Monday

Stocks in focus: Abivax, Marygold and Neuphoria report losses; Accenture partners with Anthropic, while Lobo Technologies posts H1 growth.read more...

4 Biotech Stocks to Watch as Potential Takeover Targets

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.

Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Abivax will report H1 earnings Sept. 21; analysts expect a $1.08 loss/share and $1.86M revenue.read more...

Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why

Abivax SA Sponsored ADR (ABVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

ABVX Stock Eyes Over Six-Month High As Investors Double Down On Abivax's Lead Drug Bet – Buyout Chatter Builds 

Abivax said underwriters have fully exercised their option to purchase an additional 960,000 American depositary shares as part of their $920 million offering.

Abivax Prices $800M Offering Of ADS – Here’s A Look At Some Key Figures

The size of the offering was increased to $800 million from the previously announced offering of $600 million in ADSs.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Bearish Sentiment

Hotter than expected

As expected

Cooler than expected

The September Producer Price Index report lands Thursday, October 15 at 8:30 AM ET, one day after CPI, with August’s reading at 5.4% year over year, as investors look for clues on inflation before the Fed’s October 27-28 meeting. How will the September PPI print compare to consensus expectations? Vote and explain your reasoning in the comments.

How will the September PPI print compare to consensus expectations?

Current Price	$87.98
Prev Close	$86.22
Open	$86.12
Dividend Yield	0.00%
50-Day Moving Average	$108.41
Beta	0.87
Avg. Volume	1.37M
PE Ratio	-14.41

52-Week High	$148.83
52-Week Low	$69.81
Market Capitalization	$7.7B
EPS (Annual)	-$5.46
Price to Book	16.77
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABVX Fundamentals